Do Early Changes to Dosing of T-DM1 Affect Outcomes in HER2-Positive Breast Cancer?
A new analysis looked at how dose interruptions or reductions of  ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

HER2 reduces the STING
The receptor tyrosine kinase HER2 inhibits STING activation and limits the immune response to DNA virus infection and cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - August 6, 2019 Category: Science Authors: Williams, E. R. Tags: STKE Editors ' Choice Source Type: news

Where Does T-DM1 Fit In First-Line Treatment for HER2-Positive Breast Cancer?
A phase III trial tested trastuzumab emtansine (T-DM1) with or without pertuzumab in patients with HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival MONARCH 2 was a Phase 3 study including both pre/peri- and postmenopausal women whose cancer progresse... Biopharmaceuticals, Oncology Eli Lilly, Verzenio, abemaciclib, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 30, 2019 Category: Pharmaceuticals Source Type: news

MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer
The polycomb group gene MEL-18 may prevent trastuzumab resistance making it a potential novel biomarker for HER2+ breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

HER2 Heterogeneity Impacts Response Rates in HER2-Positive Breast Cancer
A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - July 19, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Nanomedicine Approach Could Offer New Way to Target HER2+ Breast Cancer
Novel research suggests that using a nano-molecularly imprinted polymer may offer a unique and effective way to treat HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Novel Conjugate Shows Promise in HER2-Expressing Cancers
Researchers tested the novel antibody-drug conjugate trastuzumab duocarmazine in patients with heavily pretreated HER2-expressing metastatic cancers, including breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Imprinted spheres fight breast cancer
(Wiley) A particularly aggressive, metastasizing form of cancer, HER2-positive breast cancer, may be treated with nanoscopic particles " imprinted " with specific binding sites for the receptor molecule HER2. As reported by Chinese researchers in the journal Angewandte Chemie, the selective binding of the nanoparticles to HER2 significantly inhibits multiplication of the tumor cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 3, 2019 Category: Cancer & Oncology Source Type: news

Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update
This study examined how the revised 2018 ASCO/CAP HER2 scoring criteria update impacted rates of HER2 equivocal and positive breast cancer diagnoses in a single institution.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2019 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

De-Escalation of Trastuzumab Remains Controversial in HER2+ Breast Cancer
After more than 7 years of follow-up, the phase III PHARE trial failed to show that 6 months of adjuvant trastuzumab therapy was noninferior to 12 months in patients with HER2+ early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Two-in-one drug combining Herceptin with chemotherapy keeps women's breast cancers at bay
(Institute of Cancer Research) Guiding chemotherapy to a tumor by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows.The two-in-one treatment kept breast cancer at bay in women with a type of the disease called HER2-positive breast cancer who had stopped responding to existing drugs. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 27, 2019 Category: International Medicine & Public Health Source Type: news

De-escalating breast cancer therapy; can some patients be spared chemotherapy?
(Baylor College of Medicine) Researchers develop molecular testing to distinguish patients who may need less from those who may need more therapy for HER2 positive breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2019 Category: International Medicine & Public Health Source Type: news

Drug Combo Slows Progression in Advanced Breast Cancer
Results seen for alpelisib plus fulvestrant in PIK3CA - mutated, HR + , HER2 − advanced breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 24, 2019 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Drug Combo Slows Progression in Advanced Breast Cancer
MONDAY, June 24, 2019 -- Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2019 Category: Pharmaceuticals Source Type: news

Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer
The new approval is for patients with germline BRCA-mutated, HER2 negative locally advanced or metastatic breast cancer.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 22, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Early Breast Cancer Highlights From ASCO 2019 Early Breast Cancer Highlights From ASCO 2019
Dr Harold Burstein highlights ASCO oral presentations on early breast cancer, featuring neoadjuvant therapy in HER2-positive disease and updated data from the TAILORx study in HR-positive disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin ® (trastuzumab)
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. (Source: World Pharma News)
Source: World Pharma News - June 17, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Shorter-term Herceptin Sufficient? No Agreement Shorter-term Herceptin Sufficient? No Agreement
Different conclusions have been drawn from similar findings, perhaps as a result of subjective margins for equivalence in HER2+ breast cancer research.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 14, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

FDA Approves Amgen And Allergan's KANJINTI ™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
Source: Amgen News Release - June 14, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Final Results of the KRISTINE Trial in HER2-Positive Breast Cancer
This phase III trial tested T-DM1 plus pertuzumab vs chemotherapy and dual HER2 blockade in patients with HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Dr. Hope S. Rugo on the SOPHIA Trial in HER2+ Breast Cancer
Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2019 Category: Cancer & Oncology Authors: Hope S. Rugo, MD Source Type: news

SU2C hails FDA approval of alpelisib and fulvestrant new breast cancer treatment
(Stand Up To Cancer) SU2C welcomed the recent Food and Drug Administration (FDA) approval of alpelisib in combination with fulvestrant, the first and only new therapy for patients with a PIK3CA mutation in HR+/HER2- advanced metastatic breast cancer in both post-menopausal women and in men. Research by one of SU2C's inaugural Dream Teams, the SU2C PI3K Dream Team: 'Targeting The PI3K Pathway In Women's Cancers' contributed to the development of this treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 11, 2019 Category: International Medicine & Public Health Source Type: news

DNA nanorobots target HER2-positive breast cancer cells
(American Chemical Society) According to the Mayo Clinic, about 20% of breast cancers make abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2). When displayed on the surface of cancer cells, this signaling protein helps them proliferate uncontrollably and is linked with a poor prognosis. Now, researchers have developed a DNA nanorobot that recognizes HER2 on breast cancer cells, targeting them for destruction. They report their results in the ACS journal Nano Letters. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 5, 2019 Category: Biology Source Type: news

Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer[1]. (Source: World Pharma News)
Source: World Pharma News - June 3, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presents new and updated results from a number of abstracts highlighting studies including the treatment of both PD-L1-positive triple-negative and HER2-positive breast cancer at the 2019 ASCO Annual Meeting, 31 May – 4 June, in Chicago, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2019 Category: Pharmaceuticals Source Type: news

Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presents new and updated results from a number of abstracts highlighting studies including the treatment of both PD-L1-positive triple-negative and HER2-positive breast cancer at the 2019 ASCO Annual Meeting, 31 May – 4 June, in Chicago, United States. (Source: Roche Media News)
Source: Roche Media News - June 3, 2019 Category: Pharmaceuticals Source Type: news

Adding ribociclib to hormone therapy extends lives of women with most common breast cancer
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the activity of proteins called cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.The study involved 672 women aged 25 to 59 when the study began who had advanced hormone-receptor positive/HER2- breast cancer. Seventy percent of the women who took the combination therapy wer...
Source: UCLA Newsroom: Health Sciences - June 1, 2019 Category: Universities & Medical Training Source Type: news

Ribociclib Addition May Benefit Women With Advanced HR-Positive Breast Cancer
The MONALEESA-7 trial tested the combination of ribociclib with endocrine therapy in premenopausal women with advanced HR-positive/HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

First PI3K Inhibitor Approved for Metastatic, Advanced Breast Cancer
Piqray approved for HR - positive, HER2 - negative, PIK3CA - mutated, metastatic or advanced breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 28, 2019 Category: Cancer & Oncology Tags: Oncology, FDA Approvals, Source Type: news

First PI3K Inhibitor, Piqray (Alpelisib), Approved for Metastatic, Advanced Breast Cancer
TUESDAY, May 28, 2019 -- Piqray (alpelisib) tablets were approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 28, 2019 Category: General Medicine Source Type: news

First PI3K Inhibitor Piqray (alpelisib) Approved for Metastatic Advanced Breast Cancer
TUESDAY, May 28, 2019 -- Piqray (alpelisib) tablets were approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 28, 2019 Category: General Medicine Source Type: news

First PI3K Inhibitor Approved for Metastatic, Advanced Breast Cancer
TUESDAY, May 28, 2019 -- Piqray (alpelisib) tablets were approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 28, 2019 Category: Pharmaceuticals Source Type: news

FDA approves alpelisib for metastatic breast cancer
On May 24, 2019, the Food and Drug Administration approved alpelisib (PIQRAY, Novartis Pharmaceuticals Corporation) in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advan (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 28, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Researchers identified novel oncogenic function for receptor linked to Alzheimer's disease
(University of Turku) Common and rare SORLA single nucleotide polymorphisms have been associated with the development of Alzheimer's disease. So far, SORLA has been mainly studied in neurons, but the new study focused on SORLA's role in cancer cells. Led by Academy Professor Johanna Ivaska, researchers from the University of Turku in Finland observed that SORLA was highly expressed in HER2 positive cancers. Removing SORLA from cancer cells severely impaired the oncogenic fitness of HER2 positive cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2019 Category: International Medicine & Public Health Source Type: news

First PI3K Inhibitor Approved for Metastatic, Advanced Breast Cancer
Piqray approved for HR-positive, HER2-negative, PIK3CA-mutated, metastatic or advanced breast cancer (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - May 28, 2019 Category: Cancer & Oncology Source Type: news

Promising Results With Trastuzumab Deruxtecan in Early HER2+ Breast Cancer
Researchers tested a novel antibody-drug conjugate known as trastuzumab deruxtecan in an expansion cohort of a phase I study of patients with advanced HER2+ breast cancer previously treated with trastuzumab emtansine. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can Some HER2-Positive Breast Cancer Patients Avoid Surgery?
Researchers tested whether certain patients with HER2-positive breast cancer may eventually be eligible for non-surgical management. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Skipping Surgery for HER2+ Breast Cancer: Which Patients? Skipping Surgery for HER2+ Breast Cancer: Which Patients?
New findings have identified factors associated with pathological complete response (pCR) following neoadjuvant treatment, which will help identify patients who could skip surgery.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 8, 2019 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Test Predicts Benefit of Chemo in ER + , HER2 − Breast Cancer
EndoPredict, a multigene test, helps predict whether adjuvant chemotherapy would be beneficial (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 8, 2019 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Pivotal phase 2 DESTINY-Breast01 trial met primary endpoint, supporting global regulatory submission plan to start in first half of fiscal year 2019 TOKYO and MUNICH and BASKING RIDGE, N.J., May 8, 2019 -- (Healthcare Sales & Marketing Network) -- Daii... Biopharmaceuticals, Oncology Daiichi Sankyo, AstraZeneca, trastuzumab deruxtecan, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2019 Category: Pharmaceuticals Source Type: news

Test Predicts Benefit of Chemo in ER & #43;, HER2 & #8722; Breast Cancer
WEDNESDAY, May 8, 2019 -- EndoPredict (EPclin) is prognostic for distant recurrence (DR) in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according to a study published online April 30... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 8, 2019 Category: Pharmaceuticals Source Type: news

Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine. (Source: World Pharma News)
Source: World Pharma News - May 8, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Roche's Kadcyla nabs adjuvant treatment indication
The data found that Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 8, 2019 Category: Pharmaceuticals Source Type: news

HercepTest Kit May Miss Some HER2+ Breast Cancers HercepTest Kit May Miss Some HER2+ Breast Cancers
A new, FDA-approved kit for determining HER2 status in breast cancer proved to be less accurate than standard tests in this study.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 7, 2019 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: A large study from a single institution
(Cancer Research UK) Upcoming publication from the British Journal of Cancer, investigating HER2 expression as a predictor of recurrence and development in patients with DCIS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2019 Category: Cancer & Oncology Source Type: news

FDA approves Roche ’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the US Food and Drug Administration (FDA) has approved Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin® (trastuzumab)-based treatment. (Source: Roche Media News)
Source: Roche Media News - May 6, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the US Food and Drug Administration (FDA) has approved Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin® (trastuzumab)-based treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - May 6, 2019 Category: Pharmaceuticals Source Type: news